MLYS
Mineralys Therapeutics, Inc.
1W: +3.0%
1M: -17.8%
3M: -34.5%
YTD: -31.1%
1Y: +52.3%
$24.62
+1.74 (+7.60%)
After Hours: $23.45 (-1.17, -4.75%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$9.8M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.6B
52W Range10.44-47.65
Volume1,067,891
Avg Volume1,224,383
Beta0.57
Dividend—
Analyst Ratings
Company Info
CEOJon Congleton
Employees51
SectorHealthcare
IndustryBiotechnology
IPO Date2023-02-10
Websitemineralystx.com
150 N. Radnor Chester Rd.
Radnor, PA 19087
US
Radnor, PA 19087
US
888-378-6240
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Latest News
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Hudson Bay Capital Management LP Invests $2.87 Million in Mineralys Therapeutics, Inc. $MLYS
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives $49.14 Consensus Target Price from Analysts
HC Wainwright Issues Optimistic Forecast for MLYS Earnings
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Rodman David Malcom | M-Exempt | 417 | $15.44 | 2026-03-17 |
| Rodman David Malcom | S-Sale | 417 | $25.65 | 2026-03-17 |
| Rodman David Malcom | M-Exempt | 417 | $15.44 | 2026-03-17 |
| Rodman David Malcom | M-Exempt | 3,542 | $10.20 | 2026-03-13 |
| Rodman David Malcom | M-Exempt | 4,167 | $14.25 | 2026-03-13 |